Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02823847
Other study ID # 2015-1030
Secondary ID NCI-2016-01073
Status Completed
Phase Early Phase 1
First received
Last updated
Start date June 30, 2016
Est. completion date July 26, 2021

Study information

Verified date February 2022
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn how a new method for performing oral (mouth) exams can help doctors check for suspicious lesions (called premalignant and malignant oral lesions [PMOL]) in the mouth of HIV-infected smokers.


Description:

If you agree to take part in this study, you will be asked to come to the clinic for 2 study visits. First Study Visit: - You will be asked questions about your history of tobacco, alcohol, and mouthwash use. You will also be asked questions about your demographic information (such as age, sex at birth, sexual orientation and gender identification, educational level, and insurance status). This interview will last about 7 minutes. - You will be asked to blow into a device that measures the amount of carbon monoxide in your lungs. Smokers may have a larger amount of carbon monoxide in their lungs. - You will be given referral information for a tobacco cessation program if you want help to stop smoking. After this first interview, you will have a standard dental exam of your mouth and throat using normal office lighting. Any suspected PMOLs will be photographed. Right after that, a second dental exam will be performed, using a hand-held fluorescent light device. This device will be shined into your mouth to help the doctor check for PMOLs. Any suspected PMOLs will be photographed under the fluorescent light. Second Study Visit (Follow-up): About 2 weeks after your first study visit, you will be asked to return to the clinic. During this visit, you will have another oral exam with both standard and fluorescent light. You will also be asked 3 questions about being enrolled in any tobacco cessation programs. If any PMOL(s) that were found during the first visit are is still present, the study staff will collect a biopsy of the PMOL tissue. The type of biopsy you have will depend on the number of PMOLs you have and their location, size, shape, and appearance. To perform this biopsy, the affected area is removed by cutting it out (possibly completely). Local anesthesia will be used. The biopsied tissue samples will be sent to the laboratory for routine testing. The results of the biopsies will be used to test the accuracy of the 2 oral exams. A dental appointment will be made with you about 7-14 days after the oral biopsy to inspect the wound and discuss the biopsy result. Length of Study: Your active study participation will be over after the second study visit. This is an investigational study. The standard oral exams are performed using FDA-approved and commercially available methods. The use of the fluorescent light is considered investigational. The performance of the PMOL follow-up biopsy is considered standard of care. Up to 80 participants will be enrolled in this research study. All will be enrolled at Bering Omega Community Services Dental Clinic.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date July 26, 2021
Est. primary completion date July 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. HIV positive individuals seeking dental care at Bering Omega/Houston Area Community Services 2. Being able to speak English and/or Spanish Exclusion Criteria: 1. patients under 18 years of age 2. patients current participation in a tobacco cessation program 3. Patients unwilling or unable to provide consent 4. Patients declining oral biopsies

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Screening Interview
Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
Device:
Carbon Monoxide Test
Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
Behavioral:
Self-Help Materials
Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
Procedure:
Visual Oral Screening Examination
Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
Direct Fluorescent Oral Visualization Examination
Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
Oral Biopsy
Premalignant and malignant oral lesions [PMOL]) still present 2 weeks after oral exam are biopsied.

Locations

Country Name City State
United States Bering Omega/Houston Area Community Services Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center Baylor College of Medicine, The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive Predictive Value for Premalignant and Malignant oral lesions (PMOL) Positive predictive value defined as the number of true positives (confirmed PMOLs) divided by the total number of suspicious lesions. 2 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1